HANGZHOU and SHAOXING, China, July 19, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis (NASH) drug candidate ASC40 (TVB-2640) in 34 Chinese subjects has been completed and data...
from PR Newswire: https://ift.tt/3fKNwbg
No comments:
Post a Comment